Teva Pharmaceutical Industries (NYSE:TEVA) Upgraded by Wall Street Zen to Buy Rating

Teva Pharmaceutical Industries (NYSE:TEVA) was upgraded by Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Saturday.

A number of other research firms have also commented on TEVA. Piper Sandler reaffirmed an “overweight” rating and issued a $42.00 price objective (up from $41.00) on shares of Teva Pharmaceutical Industries in a research note on Thursday, April 30th. Barclays upped their price objective on shares of Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the company an “overweight” rating in a research note on Wednesday, May 6th. Truist Financial upped their price objective on shares of Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the company a “buy” rating in a research note on Thursday, April 30th. Bank of America upped their price objective on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, April 9th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research note on Monday, April 20th. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $41.78.

Teva Pharmaceutical Industries Trading Down 0.6%

TEVA opened at $34.21 on Friday. Teva Pharmaceutical Industries has a fifty-two week low of $14.99 and a fifty-two week high of $37.35. The company has a debt-to-equity ratio of 1.70, a current ratio of 1.01 and a quick ratio of 0.78. The firm has a market capitalization of $39.34 billion, a price-to-earnings ratio of 25.72, a PEG ratio of 3.51 and a beta of 0.84. The company’s 50 day moving average price is $32.82 and its two-hundred day moving average price is $31.63.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Tuesday, March 31st. The company reported $0.53 earnings per share for the quarter. Teva Pharmaceutical Industries had a net margin of 9.01% and a return on equity of 43.53%. The firm had revenue of $3.98 billion for the quarter. As a group, research analysts predict that Teva Pharmaceutical Industries will post 2.36 earnings per share for the current year.

Insider Activity at Teva Pharmaceutical Industries

In related news, EVP Eliyahu Sharon Kalif sold 153,251 shares of the business’s stock in a transaction on Thursday, May 14th. The shares were sold at an average price of $35.61, for a total transaction of $5,457,268.11. Following the transaction, the executive vice president owned 172,184 shares in the company, valued at $6,131,472.24. The trade was a 47.09% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Mark Sabag sold 144,180 shares of the business’s stock in a transaction on Friday, May 1st. The shares were sold at an average price of $34.99, for a total transaction of $5,044,858.20. Following the transaction, the insider owned 80,760 shares in the company, valued at $2,825,792.40. The trade was a 64.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 421,470 shares of company stock worth $14,570,945 over the last ninety days. 0.54% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Avidity Partners Management LP lifted its position in shares of Teva Pharmaceutical Industries by 7.9% during the 1st quarter. Avidity Partners Management LP now owns 450,100 shares of the company’s stock valued at $13,557,000 after acquiring an additional 32,800 shares during the period. Alpine Woods Capital Investors LLC lifted its position in shares of Teva Pharmaceutical Industries by 98.3% during the 1st quarter. Alpine Woods Capital Investors LLC now owns 29,424 shares of the company’s stock valued at $886,000 after acquiring an additional 14,587 shares during the period. Glenmede Trust Co. NA lifted its position in shares of Teva Pharmaceutical Industries by 486.3% during the 1st quarter. Glenmede Trust Co. NA now owns 53,377 shares of the company’s stock valued at $1,608,000 after acquiring an additional 44,273 shares during the period. Axiom Investment Management LLC acquired a new position in shares of Teva Pharmaceutical Industries during the 1st quarter valued at $965,000. Finally, Western Wealth Management LLC acquired a new position in shares of Teva Pharmaceutical Industries during the 1st quarter valued at $43,000. Institutional investors and hedge funds own 54.05% of the company’s stock.

More Teva Pharmaceutical Industries News

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Teva reported new real-world survey data showing AUSTEDO and AUSTEDO XR improved quality-of-life measures for Huntington’s disease chorea patients and reduced caregiver strain, supporting the outlook for one of its key branded medicines. Article Title
• Positive Sentiment: Teva expanded its European biosimilars business with the launch of AHZANTIVE, strengthening its growth strategy and broadening its presence in ophthalmology. Article Title
• Neutral Sentiment: Industry coverage highlighted Teva as a generic-drug stock to watch as biosimilars, complex generics and specialty drugs become increasingly important growth drivers. Article Title

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.